WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome

María I. Nunez, Daniel G. Rosen, John H. Ludes-Meyers, Martín C. Abba, Hyunsuk Kil, Robert Page, Andres J.P. Klein-Szanto, Andrew K. Godwin, Jinsong Liu, Gordon Mills, C. Marcelo Aldaz

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Background: The putative tumor suppressor WWOX gene spans the common chromosomal fragile site 16D (FRA16D) at chromosome area 16q23.3-24.1. This region is a frequent target for loss of heterozygosity and chromosomal rearrangement in ovarian, breast, hepatocellular, prostate carcinomas and other neoplasias. The goal of these studies was to evaluate WWOX protein expression levels in ovarian carcinomas to determine if they correlated with clinico-pathological parameters, thus providing additional support for WWOX functioning as a tumor suppressor. Methods: We performed WWOX protein expression analyses by means of immunobloting and immunohistochemistry on normal ovaries and specific human ovarian carcinoma Tissue Microarrays (n = 444). Univariate analysis of clinical-pathological parameters based on WWOX staining was determined by χ2 test with Yates' correction. The basic significance level was fixed at p < 0.05. Results: Immunoblotting analysis from normal ovarian samples demonstrated consistently strong WWOX expression while 37% ovarian carcinomas showed reduced or undetectable WWOX protein expression levels. The immunohistochemistry of normal human ovarian tissue sections confirmed strong WWOX expression in ovarian surface epithelial cells and in epithelial inclusion cysts within the cortex. Out of 444 ovarian carcinoma samples analyzed 30% of tumors showed lack of or barely detectable WWOX expression. The remaining ovarian carcinomas (70%) stained moderately to strongly positive for this protein. The two histotypes showing significant loss of WWOX expression were of the Mucinous (70%) and Clear Cell (42%) types. Reduced WWOX expression demonstrated a significant association with clinical Stage IV (FIGO) (p = 0.007), negative Progesterone Receptor (PR) status (p = 0.008) and shorter overall survival (p = 0.03). Conclusion: These data indicate that WWOX protein expression is highly variable among ovarian carcinoma histotypes. It was also observed that subsets of ovarian tumors demonstrated loss of WWOX expression and is potentially associated with patient outcome.

Original languageEnglish (US)
Article number64
JournalBMC Cancer
Volume5
DOIs
StatePublished - Jun 27 2005
Externally publishedYes

Fingerprint

Carcinoma
Proteins
Neoplasms
Immunohistochemistry
Loss of Heterozygosity
Progesterone Receptors
Tumor Suppressor Genes
Immunoblotting
Cysts
Prostate
Hepatocellular Carcinoma
Ovary
Breast
Chromosomes
Epithelial Cells
Staining and Labeling
Survival

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Nunez, M. I., Rosen, D. G., Ludes-Meyers, J. H., Abba, M. C., Kil, H., Page, R., ... Aldaz, C. M. (2005). WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer, 5, [64]. https://doi.org/10.1186/1471-2407-5-64

WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. / Nunez, María I.; Rosen, Daniel G.; Ludes-Meyers, John H.; Abba, Martín C.; Kil, Hyunsuk; Page, Robert; Klein-Szanto, Andres J.P.; Godwin, Andrew K.; Liu, Jinsong; Mills, Gordon; Aldaz, C. Marcelo.

In: BMC Cancer, Vol. 5, 64, 27.06.2005.

Research output: Contribution to journalArticle

Nunez, MI, Rosen, DG, Ludes-Meyers, JH, Abba, MC, Kil, H, Page, R, Klein-Szanto, AJP, Godwin, AK, Liu, J, Mills, G & Aldaz, CM 2005, 'WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome', BMC Cancer, vol. 5, 64. https://doi.org/10.1186/1471-2407-5-64
Nunez, María I. ; Rosen, Daniel G. ; Ludes-Meyers, John H. ; Abba, Martín C. ; Kil, Hyunsuk ; Page, Robert ; Klein-Szanto, Andres J.P. ; Godwin, Andrew K. ; Liu, Jinsong ; Mills, Gordon ; Aldaz, C. Marcelo. / WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. In: BMC Cancer. 2005 ; Vol. 5.
@article{c9c6f0adea784c2b9d5a605f10012169,
title = "WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome",
abstract = "Background: The putative tumor suppressor WWOX gene spans the common chromosomal fragile site 16D (FRA16D) at chromosome area 16q23.3-24.1. This region is a frequent target for loss of heterozygosity and chromosomal rearrangement in ovarian, breast, hepatocellular, prostate carcinomas and other neoplasias. The goal of these studies was to evaluate WWOX protein expression levels in ovarian carcinomas to determine if they correlated with clinico-pathological parameters, thus providing additional support for WWOX functioning as a tumor suppressor. Methods: We performed WWOX protein expression analyses by means of immunobloting and immunohistochemistry on normal ovaries and specific human ovarian carcinoma Tissue Microarrays (n = 444). Univariate analysis of clinical-pathological parameters based on WWOX staining was determined by χ2 test with Yates' correction. The basic significance level was fixed at p < 0.05. Results: Immunoblotting analysis from normal ovarian samples demonstrated consistently strong WWOX expression while 37{\%} ovarian carcinomas showed reduced or undetectable WWOX protein expression levels. The immunohistochemistry of normal human ovarian tissue sections confirmed strong WWOX expression in ovarian surface epithelial cells and in epithelial inclusion cysts within the cortex. Out of 444 ovarian carcinoma samples analyzed 30{\%} of tumors showed lack of or barely detectable WWOX expression. The remaining ovarian carcinomas (70{\%}) stained moderately to strongly positive for this protein. The two histotypes showing significant loss of WWOX expression were of the Mucinous (70{\%}) and Clear Cell (42{\%}) types. Reduced WWOX expression demonstrated a significant association with clinical Stage IV (FIGO) (p = 0.007), negative Progesterone Receptor (PR) status (p = 0.008) and shorter overall survival (p = 0.03). Conclusion: These data indicate that WWOX protein expression is highly variable among ovarian carcinoma histotypes. It was also observed that subsets of ovarian tumors demonstrated loss of WWOX expression and is potentially associated with patient outcome.",
author = "Nunez, {Mar{\'i}a I.} and Rosen, {Daniel G.} and Ludes-Meyers, {John H.} and Abba, {Mart{\'i}n C.} and Hyunsuk Kil and Robert Page and Klein-Szanto, {Andres J.P.} and Godwin, {Andrew K.} and Jinsong Liu and Gordon Mills and Aldaz, {C. Marcelo}",
year = "2005",
month = "6",
day = "27",
doi = "10.1186/1471-2407-5-64",
language = "English (US)",
volume = "5",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

TY - JOUR

T1 - WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome

AU - Nunez, María I.

AU - Rosen, Daniel G.

AU - Ludes-Meyers, John H.

AU - Abba, Martín C.

AU - Kil, Hyunsuk

AU - Page, Robert

AU - Klein-Szanto, Andres J.P.

AU - Godwin, Andrew K.

AU - Liu, Jinsong

AU - Mills, Gordon

AU - Aldaz, C. Marcelo

PY - 2005/6/27

Y1 - 2005/6/27

N2 - Background: The putative tumor suppressor WWOX gene spans the common chromosomal fragile site 16D (FRA16D) at chromosome area 16q23.3-24.1. This region is a frequent target for loss of heterozygosity and chromosomal rearrangement in ovarian, breast, hepatocellular, prostate carcinomas and other neoplasias. The goal of these studies was to evaluate WWOX protein expression levels in ovarian carcinomas to determine if they correlated with clinico-pathological parameters, thus providing additional support for WWOX functioning as a tumor suppressor. Methods: We performed WWOX protein expression analyses by means of immunobloting and immunohistochemistry on normal ovaries and specific human ovarian carcinoma Tissue Microarrays (n = 444). Univariate analysis of clinical-pathological parameters based on WWOX staining was determined by χ2 test with Yates' correction. The basic significance level was fixed at p < 0.05. Results: Immunoblotting analysis from normal ovarian samples demonstrated consistently strong WWOX expression while 37% ovarian carcinomas showed reduced or undetectable WWOX protein expression levels. The immunohistochemistry of normal human ovarian tissue sections confirmed strong WWOX expression in ovarian surface epithelial cells and in epithelial inclusion cysts within the cortex. Out of 444 ovarian carcinoma samples analyzed 30% of tumors showed lack of or barely detectable WWOX expression. The remaining ovarian carcinomas (70%) stained moderately to strongly positive for this protein. The two histotypes showing significant loss of WWOX expression were of the Mucinous (70%) and Clear Cell (42%) types. Reduced WWOX expression demonstrated a significant association with clinical Stage IV (FIGO) (p = 0.007), negative Progesterone Receptor (PR) status (p = 0.008) and shorter overall survival (p = 0.03). Conclusion: These data indicate that WWOX protein expression is highly variable among ovarian carcinoma histotypes. It was also observed that subsets of ovarian tumors demonstrated loss of WWOX expression and is potentially associated with patient outcome.

AB - Background: The putative tumor suppressor WWOX gene spans the common chromosomal fragile site 16D (FRA16D) at chromosome area 16q23.3-24.1. This region is a frequent target for loss of heterozygosity and chromosomal rearrangement in ovarian, breast, hepatocellular, prostate carcinomas and other neoplasias. The goal of these studies was to evaluate WWOX protein expression levels in ovarian carcinomas to determine if they correlated with clinico-pathological parameters, thus providing additional support for WWOX functioning as a tumor suppressor. Methods: We performed WWOX protein expression analyses by means of immunobloting and immunohistochemistry on normal ovaries and specific human ovarian carcinoma Tissue Microarrays (n = 444). Univariate analysis of clinical-pathological parameters based on WWOX staining was determined by χ2 test with Yates' correction. The basic significance level was fixed at p < 0.05. Results: Immunoblotting analysis from normal ovarian samples demonstrated consistently strong WWOX expression while 37% ovarian carcinomas showed reduced or undetectable WWOX protein expression levels. The immunohistochemistry of normal human ovarian tissue sections confirmed strong WWOX expression in ovarian surface epithelial cells and in epithelial inclusion cysts within the cortex. Out of 444 ovarian carcinoma samples analyzed 30% of tumors showed lack of or barely detectable WWOX expression. The remaining ovarian carcinomas (70%) stained moderately to strongly positive for this protein. The two histotypes showing significant loss of WWOX expression were of the Mucinous (70%) and Clear Cell (42%) types. Reduced WWOX expression demonstrated a significant association with clinical Stage IV (FIGO) (p = 0.007), negative Progesterone Receptor (PR) status (p = 0.008) and shorter overall survival (p = 0.03). Conclusion: These data indicate that WWOX protein expression is highly variable among ovarian carcinoma histotypes. It was also observed that subsets of ovarian tumors demonstrated loss of WWOX expression and is potentially associated with patient outcome.

UR - http://www.scopus.com/inward/record.url?scp=26844437227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26844437227&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-5-64

DO - 10.1186/1471-2407-5-64

M3 - Article

C2 - 15982416

AN - SCOPUS:26844437227

VL - 5

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 64

ER -